AIRLINK 190.95 Decreased By ▼ -3.88 (-1.99%)
BOP 9.77 Decreased By ▼ -0.04 (-0.41%)
CNERGY 7.85 Increased By ▲ 0.49 (6.66%)
FCCL 40.25 Increased By ▲ 1.67 (4.33%)
FFL 16.73 Increased By ▲ 0.28 (1.7%)
FLYNG 28.10 Increased By ▲ 0.56 (2.03%)
HUBC 132.39 Increased By ▲ 0.64 (0.49%)
HUMNL 13.85 Decreased By ▼ -0.01 (-0.07%)
KEL 4.60 Decreased By ▼ -0.06 (-1.29%)
KOSM 6.63 Decreased By ▼ -0.03 (-0.45%)
MLCF 47.20 Increased By ▲ 1.81 (3.99%)
OGDC 213.40 Decreased By ▼ -0.59 (-0.28%)
PACE 6.87 Increased By ▲ 0.01 (0.15%)
PAEL 40.37 Increased By ▲ 0.31 (0.77%)
PIAHCLA 17.23 Increased By ▲ 0.44 (2.62%)
PIBTL 8.40 Increased By ▲ 0.08 (0.96%)
POWER 9.60 Increased By ▲ 0.17 (1.8%)
PPL 181.45 Decreased By ▼ -0.74 (-0.41%)
PRL 41.75 Decreased By ▼ -0.08 (-0.19%)
PTC 24.72 Increased By ▲ 0.16 (0.65%)
SEARL 104.75 Increased By ▲ 2.22 (2.17%)
SILK 0.99 Decreased By ▼ -0.01 (-1%)
SSGC 39.60 Increased By ▲ 0.16 (0.41%)
SYM 17.20 Decreased By ▼ -0.13 (-0.75%)
TELE 8.81 Increased By ▲ 0.05 (0.57%)
TPLP 12.69 Decreased By ▼ -0.06 (-0.47%)
TRG 66.61 Increased By ▲ 1.21 (1.85%)
WAVESAPP 11.35 Increased By ▲ 0.24 (2.16%)
WTL 1.79 Increased By ▲ 0.09 (5.29%)
YOUW 4.04 Increased By ▲ 0.10 (2.54%)
BR100 11,983 Increased By 9 (0.08%)
BR30 36,315 Increased By 168.3 (0.47%)
KSE100 113,625 Increased By 181.8 (0.16%)
KSE30 35,671 Increased By 35.2 (0.1%)

The European Commission has approved Novartis' Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday. Entresto is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate it could have annual sales of some $5.4 billion by 2020.

Copyright Reuters, 2015

Comments

Comments are closed.